Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus X TROZINE L A.
BROMPHENIRAMINE MALEATE vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category C
Category C
Antihistamine
Antihistamine